Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Lanperisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.66 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.66 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.66 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.66 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.66 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.63 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.63 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.63 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.63 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.55 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.46 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.44 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | MC4R | P32245 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lanperisone SCHEMBL1987393 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| Lanperisone SCHEMBL5819917 | 0.99 | CHRM2 (0.68) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| Lanperisone SCHEMBL570832 | 0.99 | CHRM2 (0.68) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| SCHEMBL9720545 | 0.97 | CHRM2 (0.70) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| SCHEMBL13058950 | 0.86 | ALDH1A1 (0.67) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| SCHEMBL9168033 | 0.86 | CHRM2 (0.69) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| SCHEMBL10851001 | 0.84 | SIGMAR1 (0.72) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| Hydrochloric Acid SCHEMBL9175906 | 0.82 | CHRM2 (0.72) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| SCHEMBL17832656 | 0.82 | CHRM2 (0.46) | ALDH1A1LMNACHRM2ADRA2BDRD3 | |
| Lanperisone SCHEMBL9820433 | 0.82 | CHRM2 (0.60) | ALDH1A1LMNACHRM2ADRA2BDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006112565-A1 | THERAPEUTIC DRUGS FOR POLLAKIURIA AND URINARY INCONTINENCE CONTAINING OPTICAL ACTIVE PROPIOPHENON AND ITS SALTS | DREAMPHARMA CORP. (KR) | 2006-10-26 | — | — | WO | claimed |
| WO-2006112565-A1 | THERAPEUTIC DRUGS FOR POLLAKIURIA AND URINARY INCONTINENCE CONTAINING OPTICAL ACTIVE PROPIOPHENON AND ITS SALTS | DREAMPHARMA CORP. (KR) | 2006-10-26 | — | — | WO | disclosed |
| JP-2000290271-A | OPTICAL PURIFICATION OF SALT OF 2-METHYL-1-(4- TRIFLUOROMETHYLPHENYL)-3-PYRROLIDINO-1-PROPANONE | NIPPON KAYAKU CO LTD | 2000-10-17 | — | — | JP | disclosed |
| EP-0770386-B1 | Lanperisone formulation | NIPPON KAYAKU KK (JP) | 2000-02-02 | — | — | EP | disclosed |
| US-5843478-A | Lanperisone formulation | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1998-12-01 | — | — | US | disclosed |
| EP-0770386-A1 | Lanperisone formulation | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1997-05-02 | — | — | EP | disclosed |
| US-5103022-A | Reacting dl-2-methyl-1-(4-trifluoromethylphenyl)-3-pyrrolidino -1-propanone with l-acetylphenylglycine to form corresponding diastereomeric salt, deposition, isolation of l-2-methyl-1-(4-trifluoromethylphenyl)-3-pyrrolidino-1-propanone | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5057535-A | Muscle relaxants | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1991-10-15 | — | — | US | disclosed |
| EP-0266577-B1 | AN OPTICALLY ACTIVE PROPANONE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME AND USE THEREOF | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1991-09-25 | — | — | EP | disclosed |
| EP-0266577-A1 | An optically active propanone derivative and process for producing the same and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1988-05-11 | — | — | EP | disclosed |